Corcept Therapeutics (CORT) Return on Capital Employed (2011 - 2026)
Corcept Therapeutics recorded quarterly Return on Capital Employed of 1.21% in Q1 2026, down 118.01% quarter-over-quarter from 6.75% in Q4 2025, and down 1704.0% year-over-year from 0.08% in Q1 2025.
Corcept Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 1.21% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1704.0% year-over-year to 1.21%; the TTM figure through Mar 2026 stood at 1.21% (down 1704.0% YoY), while the FY2025 annual figure was 6.66%, down 1654.0% from the prior year.
- Return on Capital Employed came in at 1.21% for Q1 2026 at Corcept Therapeutics, down from 6.75% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 33.86% in Q1 2022 to a low of 1.21% in Q1 2026.
- A 5-year average of 19.58% and a median of 21.32% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed jumped 1274 bps in 2022 and slumped 1704 bps in 2026, its largest moves.
- Corcept Therapeutics' Return on Capital Employed stood at 23.18% in 2022, then slipped by 8 bps to 21.32% in 2023, then slipped by 4 bps to 20.39% in 2024, then sank by 67 bps to 6.75% in 2025, then plunged by 118 bps to 1.21% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 1.21%, 6.75%, and 10.24% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Corcept Therapeutics | 7.26 Bn | 6.92 Bn | 162.02 Mn | -1.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.21% |
| Dec 31, 2025 | 6.75% |
| Sep 30, 2025 | 10.24% |
| Jun 30, 2025 | 15.01% |
| Mar 31, 2025 | 15.83% |
| Dec 31, 2024 | 20.39% |
| Sep 30, 2024 | 23.00% |
| Jun 30, 2024 | 21.89% |
| Mar 31, 2024 | 22.52% |
| Dec 31, 2023 | 21.32% |
| Sep 30, 2023 | 22.43% |
| Jun 30, 2023 | 20.68% |
| Mar 31, 2023 | 19.30% |
| Dec 31, 2022 | 23.18% |
| Sep 30, 2022 | 27.46% |
| Jun 30, 2022 | 30.26% |
| Mar 31, 2022 | 33.86% |
| Dec 31, 2021 | 27.24% |
| Sep 30, 2021 | 22.23% |
| Jun 30, 2021 | 20.74% |
| Mar 31, 2021 | 21.12% |
| Dec 31, 2020 | 25.36% |
| Sep 30, 2020 | 28.06% |
| Jun 30, 2020 | 32.83% |
| Mar 31, 2020 | 33.02% |
| Dec 31, 2019 | 31.81% |
| Sep 30, 2019 | 32.17% |
| Jun 30, 2019 | 31.10% |
| Mar 31, 2019 | 31.04% |
| Dec 31, 2018 | 33.13% |
| Sep 30, 2018 | 34.96% |
| Jun 30, 2018 | 33.78% |
| Mar 31, 2018 | 33.88% |
| Dec 31, 2017 | 38.85% |
| Sep 30, 2017 | 48.72% |
| Jun 30, 2017 | 42.31% |
| Mar 31, 2017 | 30.95% |
| Dec 31, 2016 | 26.46% |
| Sep 30, 2016 | 24.19% |
| Jun 30, 2016 | 14.04% |
| Mar 31, 2016 | 4.15% |
| Dec 31, 2015 | -11.77% |
| Sep 30, 2015 | -27.61% |
| Jun 30, 2015 | -43.34% |
| Mar 31, 2015 | -72.55% |
| Dec 31, 2014 | -123.64% |
| Sep 30, 2014 | -122.22% |
| Jun 30, 2014 | -111.05% |
| Mar 31, 2014 | -101.64% |
| Dec 31, 2013 | -76.38% |
| Sep 30, 2013 | -63.54% |
| Jun 30, 2013 | -52.62% |
| Mar 31, 2013 | -42.37% |
| Dec 31, 2012 | -38.59% |
| Sep 30, 2012 | -54.45% |
| Jun 30, 2012 | -100.14% |
| Mar 31, 2012 | -95.96% |
| Dec 31, 2011 | -84.91% |
| Sep 30, 2011 | -64.54% |